SG Americas Securities
DRNA

SG Americas Securities’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

SG Americas Securities’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44,429
Closed -$896K – 3983
2021
Q3 		$896K Buy
44,429
+24,910
+128% +$688K ﹤0.01% 2000
2021
Q2 		$728K Sell
19,519
-1,531
-7% -$46.9K ﹤0.01% 1753
2021
Q1 		$538K Sell
21,050
-10,944
-34% -$280K ﹤0.01% 1983
2020
Q4 		$705K Sell
31,994
-2,190
-6% -$48.2K ﹤0.01% 1737
2020
Q3 		$615K Buy
34,184
+9,250
+37% +$192K ﹤0.01% 1499
2020
Q2 		$633K Buy
24,934
+8,948
+56% +$193K 0.01% 1863
2020
Q1 		$294K Buy
15,986
+7,069
+79% +$137K ﹤0.01% 2249
2019
Q4 		$196K Sell
8,917
-2,479
-22% -$49.9K ﹤0.01% 2491
2019
Q3 		$164K Sell
11,396
-14,403
-56% -$206K ﹤0.01% 2457
2019
Q2 		$406K Sell
25,799
-13,026
-34% -$177K ﹤0.01% 2011
2019
Q1 		$569K Buy
+38,825
New +$446K 0.01% 1736

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

SG Americas Securities's DRNA Position: Q4 2021 in Review

SG Americas Securities sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 44,429 shares — an estimated $896K sold.

SG Americas Securities first reported a position in DRNA in Q1 2019 and held it in 11 quarters. The position peaked at $896K in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • SG Americas Securities reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • SG Americas Securities sold 44,429 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $896K.
  • SG Americas Securities first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 11 quarters.
  • SG Americas Securities's Dicerna Pharmaceuticals, Inc. position peaked at $896K in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.